Vaccine apartheid: the separation of the world’s poorest and most vulnerable and the birth of Omicron

Vaccine apartheid: background

The inequitable distribution of vaccination in the case of the COVID-19 pandemic appears to be a relatively new problem but this ‘apartheid’ has prevailed for a longtime. With the examples from the past of pandemics like HIV at the end of the 20th century and the swine flu pandemic of 2009, this outcome was expected. The WHO Director General reminisced about these pandemics and how the anti-retroviral drugs for HIV reached the LMICs 10 years after their discovery resulting in the prolongation of the HIV crisis in the Global South. This was followed by the H1N1 influenza pandemic, in 2009, where similar circumstances developed. ⁶ Tedros called these incidents a ‘global failure’. Similarly, WHO’s Chief Scientist Swaminathan also recalls how these inequalities hark back to the 1990s when she saw her HIV patients in India die when the drugs were saving lives in the west. ⁷

Although COVAX, a worldwide initiative aimed at equitable access to COVID-19 vaccines, co-led by Gavi, the Coalition for Epidemic Preparedness Innovation (CEPI), and the WHO, was launched to ensure this segregation is not carried into the current pandemic, it does not seem to be anywhere near achieving its goal. The major reasons for it are disparity in vaccine deployment infrastructure of HICs and LMICs, the prevalence of vaccine nationalism, and the facility’s at-risk funding strategy.^8,9 Swaminathan, WHO’s Chief Scientist says that COVAX was a beautiful idea that failed to deliver its goal because none of the manufacturers prioritized it. ¹⁰

India and South Africa proposed at the World Trade Organization to temporarily suspend the intellectual property rights of the COVID-19 vaccines. However, they were met with resistance from many of the HICs like the United Kingdom, Canada, and the European Union. These countries have procured 8.2, 10.1, and 6.9 doses of COVID-19 vaccines respectively for each individual as of December 2020. ¹¹ On the contrary, LMICs like Cambodia, Pakistan, Mauritius, Albania, Ecuador, Guyana, and Bolivia had received less than 0.1 doses as of February 2021. ¹² In these times, much is to be learned from mankind’s triumph against the poliovirus. In the early 1950s, Dr. Jonas Salk first made the Salk vaccine. Later when asked who owned the patent for it, he said ‘The people, I would say. There is no patent. Could you patent the sun?’ The disease has been completely eradicated from the world since then, with the polio vaccines being part of mandatory vaccination schedules across the globe. There were only 32 reported cases of Polio in 2021 comparison to more than 60,000 cases of death and paralysis in 1950s from polio in United States alone. ¹³

In recent times, the outbreaks of Ebola virus disease, Lassa fever, hantavirus, the emergence of multidrug-resistant tuberculosis, severe acute respiratory syndrome (SARS), and other diseases have transcended national boundaries. These examples should work to further strengthen the narrative that ‘no one is safe until everyone is safe’. ¹⁴

Global scenario: consequences

Amid the application of COVAX to address the prevailing gap on equitable access to COVID-19 vaccines between HICs and LMICs, there is still an unequal allocation of vaccines. According to Our World in Data, at least one dose of the COVID-19 vaccination has been given to 65.7% of the world’s population. Globally, 11.74 billion doses have been administered, with 7.24 million doses being administered every day. In low-income nations, just 15.9% of people have received at least one dosage, as of 19 May 2022. ¹⁵ The first-world countries have been focusing on developing and rolling out COVID-19 vaccines to protect their own populations first, rather than sharing the vaccines for the sake of all mankind. For example, the low vaccination rates in the LMICs pose another pressing issue that contributes to the affordability of the rollout of COVID-19 vaccines to these countries. ² The rampant increase of COVID-19 cases in India contributed to an increased demand for vaccines and a limitation in the manufacturing capacity of vaccines globally. The allocation of these vaccines to this country have been redirected toward the domestic market, and hence, another repercussion worldwide. ¹⁶

If this situation keeps going on with a slow pace of vaccination rate, there will still be millions of unvaccinated people at high risk of facing the consequences of COVID-19 pandemic (deaths, burdened healthcare infrastructure, and record high physician burnouts). ¹⁷ With the continuing prevalence of SARS-CoV-2 and the advent of new variants of this virus that have the potential to have immune evasions, such as Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), Epsilon (B.1.427/B.1.1429), Zeta (P.2), Eta (B.1.525), Theta (P3), Iota (B.1.526), Kappa (B.1.617.1), and Omicron (B.1.1.529), it is highly likely that another emergence of pandemics will happen.^18,19 This vaccine apartheid is a reflection of the failure of wealthy nations to equally distribute the sources of COVID-19 vaccines globally. Normality is slowly coming back to vaccine front-runners like the United Kingdom, Israel, and United States, but in developing countries like India, the health system is still buckling under pressure with many recorded deaths every day. ²⁰ This however in the longer run might pose serious problem to HICs; as the virus continues to mutate, there is a possibility of the current vaccines being less effective against it.

The way ahead

HICs vaccinate an exceedingly large portion of their populations, stocking up on vaccines, their boosters, boosters on boosters, and while this may help them contain the virus preventing any major outbreaks within their own borders but the countries with limited vaccine coverage like Yemen, Syria, and countries from the midsection of Africa including Senegal are now pushing their entire health infrastructure and professionals to their limits beyond which a complete collapse is imminent.^21–23 In an open letter appeal to G20 summit leaders, the disparity between access to vaccines between HICs and LMICs were brought to everyone’s attention. It stated that there were only four doses per a hundred people in LMICs in comparison to an extra 133 doses per hundred in HICs. ²⁴ It should be a strong point in argument that, for their own self-interests, rich countries should help disseminate vaccines broadly. The lead policy and geo-political leaders of the country should be educated and made aware of the established link between vaccine apartheid and mushrooming of new variants, which each time will create a new wave of infections, hospitalization, and mortality, unsettling their local equilibrium. Since there is a constant risk of infection among even vaccinated immuno-compromised and geriatric population, the developed nations hold as much as an equal threat of giving birth to the next variant with lesser vaccine coverage as LMICs. ²⁵ Since neither of the current vaccines provides a definite immunity against the infection, even more so with the recent variants of delta and Omicron, the probability of the virus mutating into a more infectious genome is higher even in highly vaccinated populations. ²⁶

The most efficient and long-term solution to this apartheid is working toward strengthening the infrastructure in the LIMCs. It is clear from this pandemic that LMICs need to build local and regional capacity and infrastructure as relying on the conscience, morality, and excess vaccine production of HICs for this or future pandemics will be a risk not worth taking. The African Vaccine Manufacturing Initiative ‘Vaccine Manufacturing and Procurement in Africa (VMPA)’ in 2017 reported approximately 100% importation of all kinds of vaccines to Africa. ²⁷ In a striking contrast to the call by WHO to support local manufacturing of flu vaccines, ²⁸ the number of local vaccine manufacturers has fallen down from 55 countries two decades ago to less than 20 in 2017. ²⁷

International initiatives working currently to disseminate vaccines to the ones in need can also aid in providing sustained efforts and guidance to prevent such episodes of mass vaccine production falling in the hands of few profit-driven commercial entities. The International Monetary Fund has begun investing in vaccine production in Africa, stating it is ‘good for the world’, since the price of investment is miniscule in contrast to the global economic and financial losses of COVID-19. ²⁹ Investment however shall not be replaced with loans since it only perpetuates indebtedness.

Conclusion

Vaccine apartheid, the inequitable distribution of vaccines leading to lower vaccination rates in LMICs, has been well-documented in the past pandemics. ³⁰ Unfortunately, mankind has failed to learn from its past mistakes leading to history being repeated in the context of the current COVID-19 pandemic. The hoarding of vaccines by the HICs and ineffective and discriminating government policies of the LMICs have contributed to this apartheid. Several LMIC countries introduced the lockdown measures very late into the pandemic and failed to implement these measures effectively. The vaccines, when introduced in a few countries, were initially hoarded for the influential members of society before being fairly administered to healthcare workers and the geriatric population. Furthermore, there were no rules about whether the foreigners present in any country at the time could access the vaccines. The consequences of these will be seen as worsening of the pandemic leading to unnecessary loss of lives, and birth of newer, more virulent variants like the Omicron. In addition, this will place more socioeconomic strain on the LMICs. To rectify this situation, initiatives must be taken involving the HICs to export their stockpiled vaccines to other countries. Higher authorities, like the WHO, should step in to roll out worldwide vaccine distribution programs and ensure that HICs adhere to these programs to prevent repeating failures. Furthermore, the establishment of an independent regulatory body is needed to check and regulate pharmaceutical companies to avert intellectual property rights over the vaccines (especially amid pandemics), and making exclusive deals with HICs. If the lessons from history are to be learned, everyone involved shall be reminded of their moral obligation and the fact that further aggravation of the pandemic will cause global harm, which is not limited to LMICs.